Rehmann Capital Advisory Group’s Celldex Therapeutics CLDX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.08K	Sell	508 -19	-4%	-$44	﹤0.01%	1543
2019 Q2	$1.41K	Hold	527	–	–	﹤0.01%	1856
2019 Q1	$2.59K	Buy	527 +165	+46%	+$868	﹤0.01%	1690
2018 Q4	$1.07K	Buy	362 +315	+670%	+$1.55K	﹤0.01%	1632
2018 Q3	$319	Sell	47 -286	-86%	-$2K	﹤0.01%	2083
2018 Q2	$2.51K	Buy	333 +265	+390%	+$3.54K	﹤0.01%	1737
2018 Q1	$2K	Buy	+68	New	+$2.63K	﹤0.01%	1709

Other funds holding CLDX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rehmann Capital Advisory Group's CLDX Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its Celldex Therapeutics (CLDX) stake by 3.6% in Q3 2019, selling an estimated $44 and leaving 508 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

Rehmann Capital Advisory Group first reported a position in CLDX in Q1 2018 and has held it in 7 quarters since. The position peaked at $2.59K in Q1 2019. 54 funds tracked by Wall St. Rank hold CLDX as of Q3 2019.

Rehmann Capital Advisory Group held 508 shares of Celldex Therapeutics worth $1.08K as of Q3 2019.
Rehmann Capital Advisory Group sold 19 Celldex Therapeutics shares in Q3 2019, an estimated $44.
Celldex Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1543 holding.
Rehmann Capital Advisory Group first reported a position in Celldex Therapeutics in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Celldex Therapeutics position peaked at $2.59K in Q1 2019.
54 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.